Evidence base

Guidelines, books and articles

The sources behind every topic — consensus guidelines, reviews and prescribing information, with the year and organisation that published them. Open a title to read it at the source.

Guideline Metabolic

Fayuvi - prescribing information

U.S. prescribing information for Fayuvi gene therapy, FDA-approved for neurologic manifestations of MPS IIIA with preserved neurodevelopmental function.

U.S. Food and Drug Administration

Article Metabolic

GeneReviews - Pompe disease (targeted treatment)

GeneReviews chapter on Pompe disease, covering CRIM status, immune tolerance induction and the targeted treatment of infantile-onset disease.

GeneReviews, University of Washington

Guideline Metabolic

Mucopolysaccharidoses (MPS) - pediatric clinical guide

A pediatric clinical guide to the mucopolysaccharidoses: recognition of the clinical pattern, biochemical and molecular testing, subtype-specific therapy, and surveillance and perioperative planning.

Pediatric metabolics / MPS clinical guide

2026

Guideline Metabolic

ACMG - Evidence-based clinical guideline for PAH deficiency

Evidence-based recommendations for phenylalanine hydroxylase deficiency, including lifelong treatment when untreated phenylalanine exceeds 360 micromol/L and a treatment target of 360 micromol/L or le

American College of Medical Genetics and Genomics

2025

Article Metabolic

GeneReviews - Mucopolysaccharidosis Type III

The Sanfilippo syndromes (MPS IIIA-D): progressive neurocognitive decline with mild somatic features, diagnosis and supportive management.

GeneReviews, University of Washington

2024

Book Dysmorphic

Noonan syndrome — GeneReviews

Peer-reviewed chapter on Noonan syndrome covering diagnosis, cardiac surveillance, management and genetic counselling.

University of Washington, NCBI Bookshelf

2024

Article Metabolic

GeneReviews - Mucopolysaccharidosis Type IVA

Morquio A syndrome: skeletal disease, the role of urinary GAGs and enzyme testing, elosulfase alfa therapy and cervical spine surveillance.

GeneReviews, University of Washington

2024

Article Metabolic

GeneReviews - Mucopolysaccharidosis Type II

The X-linked Hunter syndrome: clinical features, enzyme and molecular testing, idursulfase therapy and the approach to neuronopathic disease.

GeneReviews, University of Washington

2024

Article Metabolic

GeneReviews - Mucopolysaccharidosis Type I

Diagnosis, management and genetic counselling for MPS I, including the severe Hurler spectrum and the role of early haematopoietic stem cell transplantation.

GeneReviews, University of Washington

2024

Article Metabolic

GeneReviews - Biotinidase deficiency

Diagnosis and treatment of biotinidase deficiency, including free biotin dosing for profound and partial deficiency and the need for hearing and vision assessment.

GeneReviews, University of Washington

2024

Book Genetic

GeneReviews

Peer-reviewed, regularly updated chapters per condition covering diagnosis, management and genetic counselling. The first place to check after the differential.

University of Washington, NCBI Bookshelf

2024

Article Metabolic

GeneReviews - Maple syrup urine disease

Clinical description, diagnosis and management of MSUD, including the inpatient branched-chain amino acid and BCAA-free formula regimen.

GeneReviews, University of Washington

2024

Article Metabolic

GeneReviews - Tyrosinemia type I

Diagnosis and management of tyrosinemia type I, including nitisinone dosing, dietary restriction and the monitoring schedule.

GeneReviews, University of Washington

2024

Guideline Metabolic

Fatty acid oxidation disorders: emergency management

Recognition and treatment of hypoketotic hypoglycaemia during fasting or febrile illness, the glucose infusion rates used to reverse catabolism, avoidance of lipid loads in the acute phase and the saf

British Inherited Metabolic Disease Group (BIMDG)

2023

Guideline Metabolic

Urea cycle disorders: diagnosis, dietary and long-term management

Diagnostic strategy for suspected urea cycle defects, protein prescription and essential amino acid supplementation, citrulline and arginine dosing, sickle-cell-style monitoring, and the sick-day plan

British Inherited Metabolic Disease Group (BIMDG)

2023

Guideline Metabolic

Emergency regimens: managing intercurrent illness at home

The emergency regimen used across inherited metabolic disorders: when to start glucose polymer drinks, volumes and intervals by age, how to record progress, and the red flags that mean the child needs

British Inherited Metabolic Disease Group (BIMDG)

2023

Guideline Metabolic

Maple syrup urine disease: emergency management

Sick-day protocol for maple syrup urine disease: withholding leucine, high-calorie glucose drinks and urgent admission for leucine removal if encephalopathy develops.

British Inherited Metabolic Disease Group (BIMDG)

2023

Guideline Metabolic

Galactosaemia: diagnosis and long-term management

Diagnosis and lifelong dietary management of galactosaemia, including the lactose-free diet and monitoring for long-term complications.

British Inherited Metabolic Disease Group (BIMDG)

2023

Guideline Metabolic

Homocystinuria: clinical and dietary management

Dietary and vitamin treatment of homocystinuria, target total homocysteine levels and monitoring for thrombotic and ocular complications.

British Inherited Metabolic Disease Group (BIMDG)

2023

Article Dysmorphic

Thanatophoric dysplasia - Orphanet disease overview

Disease overview of thanatophoric dysplasia: definition, epidemiology, prenatal ultrasound findings, inheritance and the differential diagnosis of the lethal dysplasias.

Orphanet

2023

Guideline Metabolic

Argininosuccinic aciduria (ASA): diagnosis and long-term management

British Inherited Metabolic Disease Group guideline on argininosuccinic aciduria (argininosuccinate lyase deficiency): confirming the diagnosis biochemically, dietary protein restriction, arginine sup

British Inherited Metabolic Disease Group (BIMDG)

2022

Guideline Metabolic

Phenylketonuria: dietary management and follow-up

Dietary treatment of phenylketonuria, target phenylalanine ranges by age, and the monitoring schedule for children and adults on a low-phenylalanine diet.

British Inherited Metabolic Disease Group (BIMDG)

2022

Guideline Metabolic

Glycogen storage disorders: emergency management

Emergency management of glycogen storage disorders during intercurrent illness, including frequent glucose polymer, cornstarch dosing and admission thresholds for hypoglycaemia.

British Inherited Metabolic Disease Group (BIMDG)

2022

Guideline Metabolic

MCAD deficiency: the emergency regimen for intercurrent illness

Home and hospital sick-day management for medium-chain acyl-CoA dehydrogenase deficiency: glucose polymer drinks at set intervals, when to escalate to intravenous glucose, and the follow-up patients a

British Inherited Metabolic Disease Group (BIMDG)

2022

Guideline Metabolic

Organic acidaemias: emergency management and long-term follow-up

Emergency treatment of propionic, methylmalonic and isovaleric acidaemia during decompensation, carnitine and vitamin B12 use, and the surveillance that matters long term: growth, cardiac function, re

British Inherited Metabolic Disease Group (BIMDG)

2022

Guideline Metabolic

Management of hyperammonaemia in urea cycle disorders

Stepwise control of plasma ammonia: stop protein intake, give intravenous glucose to suppress catabolism, add nitrogen scavengers, and move to extracorporeal removal when ammonia stays above the agree

British Inherited Metabolic Disease Group (BIMDG)

2022